**Veru Inc. Settles Outstanding Promissory Notes with Onconetix, Inc.** Veru Inc. has announced the termination of its outstanding loan agreements with Onconetix, Inc. (formerly Blue Water Vaccines Inc.), following a recently executed Settlement Agreement. As of September 22, 2025, a total of $8.8 million was owed to Veru under two promissory notes related to a previous asset purchase. Under the terms of the settlement, Veru agreed to accept a reduced cash payment of approximately $6.3 million, along with 3,125 shares of Onconetix's Series D Convertible Preferred Stock (valued at $1,000 per share) and 846,975 warrants to purchase common stock, in full satisfaction of all outstanding obligations. The transaction was completed on September 24, 2025, with all related agreements and notes officially terminated upon payment. There is no assurance as to the timing or amount of any future proceeds Veru may receive from the preferred shares or warrants.